Tag: absence

MILLER INDUSTRIES ANNOUNCES WORKFORCE REDUCTION

CHATTANOOGA, Tenn., Aug. 14, 2025 /PRNewswire/ -- Miller Industries, Inc. (NYSE: MLR) (the "Company") announced today that it will reduce its workforce by approximately...

AIMIA REPORTS SECOND QUARTER 2025 RESULTS; RE-ITERATES AEBITDA GUIDANCE AND LOWERS HOLDCO COST TARGET FOR THE YEAR

TORONTO, Aug. 14, 2025 /CNW/ - Aimia Inc, (TSX: AIM) ("Aimia" or the "Company"), today reported its financial results for the three and six months...

Neuro Sharp Gains Recognition in 2025 as Your Ultimate Brain Enhancement Formula

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

DRI Healthcare Reports Second Quarter 2025 Results

Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...

AlphaCur Gains Momentum in 2025 as a Leading Formula for Neuropathy Nerve Health Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

Mattr Announces Second Quarter 2025 Results

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2025. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and interim consolidated financial statements for the six months ended June 30, 2025, which are available on the Company’s website and at www.sedarplus.ca.

Terrestrial Energy Selected for DOE Office of Nuclear Energy Advanced Reactor Pilot Program for Accelerated Development

Advanced Reactor Pilot Program launched by DOE to expedite authorization and commercialization of advanced nuclear reactor designs

G. WILLI-FOOD INTERNATIONAL REPORTS THE RESULTS OF SECOND QUARTER 2025 WITH RECORD HIGH RESULTS

THE COMPANY REPORT ITS HIGHEST-EVER QUARTERLY REVENUE, OPERATING PROFIT, PROFIT BEFORE TAX, AND NET INCOME YAVNE, Israel, Aug. 12, 2025 /PRNewswire/ -- G. Willi-Food International...

China Literature Announces 2025 Interim Results

HONG KONG, Aug. 12, 2025 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual...

Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

Franco-Nevada Reports Record Q2 2025 Results

Acquisitions Increase Growth Outlook (in U.S. dollars unless otherwise noted) TORONTO, Aug. 9, 2025 /PRNewswire/ - "I am very pleased with our record financial results this...

KeySlim Drops Explores Ingredient-First Weight Management Trends in 2025

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

Dorel annonce ses résultats du deuxième trimestre de 2025

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Les Industries Dorel inc. (TSX : DII.B, DII.A) a annoncé aujourd'hui ses résultats financiers pour le deuxième trimestre et les six mois clos le 30 juin 2025.

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.

Crédit Agricole Financement de l’Habitat SFH : EARLY REPURCHASE OF ISIN FR001400JM17

Regulatory release no. 4 – 2026: Correction. Result of InstallatørGruppen A/S’ Initial Public Offering on Nasdaq Copenhagen

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...